Belite Bio begins FDA rolling submission for Stargardt disease treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Belite Bio begins FDA rolling submission for Stargardt disease treatment
(NASDAQ: BLTE) Delayed: 145.13 -1.94 (1.32%)
Previous Close $147.07    52 Week High $ 
Open $145.94    52 Week Low $ 
Day High $148.65    P/E N/A 
Day Low $144.64    EPS $ 
Volume 161,171